Evangelisches Krankenhaus Hamm

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

Hematological Malignancy, Lymphoid Neoplasia, Elderly Patients +7

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo et al. · The Lancet Oncology · 2016 · 613 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al. · Leukemia · 2012 · 416 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Health Sciences +10

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

Michael Untch, Christian Jackisch, Andreas Schneeweiß et al. · The Lancet Oncology · 2016 · 408 citations

Breast Oncology, Oncology, Early Breast Cancer +7

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

Alice Fabarius, Armin Leitner, Andreas Hochhaus et al. · Blood · 2011 · 286 citations